Drug Development

NIH Grant Supports Anti-HIV Drug Discovery Program

Published in AIDS Weekly, October 16th, 2000

Salus Therapeutics Inc. announced that the company has received a $96,600 Phase I Small Business Innovation Research (SBIR) grant award from the National Institute of Allergy and Infectious Diseases of the U.S. National Institutes of Health.

This award will support the company's anti-HIV drug discovery program. Senior scientist Zhidong Chen, PhD, will be the principal investigator on the project.

Despite the effectiveness of current antiviral chemotherapies, treatment failure occurs at rates as high as 20%-50% due to drug toxicity and/or development of drug resistance.

"Salus will use novel technology to identify nucleic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-10-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry